Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals. It develops Fycompa, an antiepileptic drug in the neurology area that is approved as an adjunctive therapy for partial-onset seizures in Japan, the United States, Europe, and Asia. The company is also approved for use as monotherapy for the treatment of partial onset seizures in the United States; and as an adjunctive therapy for primary generalized tonic-clonic seizures in Japan, the United States, Europe, and Asia. It also offers Aricept for the treatment of Alzheimer's disease/dementia with Lewy bodies worldwide; and BELVIQ, an antiobesity agent in the United States. In addition, it develops Halaven, an anticancer agent in the oncology area for use in the treatment of breast cancer in approximately 65 countries and also for use in the treatment of malignant soft tissue sarcoma in 50 countries; and Lenvima, an anticancer agent for use in the treatment of thyroid cancer in Japan, the United States, Europe, and Asia. Further, the company has been approved as combination therapy with everolimus for use in the treatment of renal cell carcinoma in the United States and Europe. It has strategic collaboration with Merck & Co., Inc. for Lenvima in the oncology and dementia fields; and with Ono Pharmaceutical Co., Ltd. for Lenvima and Opdivo combination therapy for the treatment of hepatocellular carcinoma, as well as Collaboration Agreement with Ono Pharmaceutical Co., Ltd. to develop a therapy for treatment of hepatocellular carcinoma. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was founded in 1941 and is headquartered in Tokyo, Japan.
Industry, Sector and Symbol
Industry Private households
Sub-IndustryN/A
SectorMedical
Phone813-3817-3700
Debt
Current Ratio2.20
Quick Ratio1.92
Price-To-Earnings
Sales & Book Value
Annual Sales$5.42 billion
Price / Sales4.32
Price / Cash Flow33.07
Price / Book4.24
Profitability
Net Income$466.60 million
Net Margins10.54%
Return on Assets6.26%
Miscellaneous
Employees10,456
OptionableNot Optionable
Eisai (OTCMKTS:ESALY) Frequently Asked Questions
What is Eisai's stock symbol?
Eisai trades on the OTCMKTS under the ticker symbol "ESALY."
How were Eisai's earnings last quarter?
Eisai Co., Ltd (OTCMKTS:ESALY) announced its quarterly earnings results on Thursday, November, 1st. The company reported $0.64 earnings per share for the quarter. The company had revenue of $1.41 billion for the quarter. Eisai had a net margin of 10.54% and a return on equity of 10.74%. View Eisai's Earnings History.
When is Eisai's next earnings date?
Has Eisai been receiving favorable news coverage?
News coverage about ESALY stock has been trending somewhat negative recently, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Eisai earned a daily sentiment score of -1.6 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the next several days.
Who are some of Eisai's key competitors?
Some companies that are related to Eisai include INDUSTRIA DE DI/ADR (IDEXY), AIRBUS SE/ADR (EADSY), NK Lukoil PAO (LUKOY), Iberdrola (IBDRY), VINCI S A/ADR (VCISY), Bayerische Motoren Werke (BAMXF), JAPAN TOB INC/ADR (JAPAY), China Shenhua Energy (CSUAY), Sun Hung Kai Properties (SUHJY), Recruit (RCRRF), PERNOD RICARD S/ADR (PDRDY), SCHNEIDER ELEC /ADR (SBGSY), SEVEN & I HOLDI/ADR (SVNDY), CK HUTCHISON HO/ADR (CKHUY) and ORIENTAL LD CO/ADR (OLCLY).
Who are Eisai's key executives?
Eisai's management team includes the folowing people:
- Mr. Haruo Naito, CEO, Representative Corp. Officer & Director (Age 71)
- Mr. Gary Hendler, Sr. VP & Pres of EMEA Region (Age 52)
- Dr. Lynn D. Kramer, VP and Chief Clinical Officer & Chief Medical Officer - Neurology Bus. Group (Age 68)
- Mr. Alexander Scott, VP, Chief Strategy Officer & Head of Strategy Dept. - Neurology Bus. Group
- Ms. Shaji Procida, VP and Pres & COO of Eisai Inc. (Age 47)
How do I buy shares of Eisai?
Shares of ESALY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Eisai's stock price today?
One share of ESALY stock can currently be purchased for approximately $78.95.
How big of a company is Eisai?
Eisai has a market capitalization of $23.28 billion and generates $5.42 billion in revenue each year. The company earns $466.60 million in net income (profit) each year or $1.63 on an earnings per share basis. Eisai employs 10,456 workers across the globe.
What is Eisai's official website?
How can I contact Eisai?
Eisai's mailing address is 4-6-10 Koishikawa Bunkyo-ku, Tokyo M0, 112-8088. The company can be reached via phone at 813-3817-3700.
MarketBeat Community Rating for Eisai (OTCMKTS ESALY)
MarketBeat's community ratings are surveys of what our community members think about Eisai and other stocks. Vote "Outperform" if you believe ESALY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ESALY will underperform the S&P 500 over the long term. You may vote once every thirty days.
